Study: Iyuzeh Demonstrated Similar IOP Lowering Efficacy with a Favorable Safety Profile when Compared to Xalatan

Thea Pharma announced the presentation of phase 3 data on Iyuzeh (latanoprost ophthalmic solution 0.005%) by Jason Bacharach, MD, at the 2023 American Glaucoma Society (AGS) Annual Meeting. The large, pivotal clinical trial demonstrated comparable efficacy of preservative-free Iyuzeh over brand-name Xalatan containing the preservative benzalkonium chloride (BAK), in patients with primary open-angle glaucoma or ocular hypertension.

“We compared Iyuzeh to Xalatan in 334 patients over 84 days,” Dr. Bacharach, founder and Director of Research at North Bay Eye Associates in Petaluma, California, said in a company news release. “Iyuzeh demonstrated similar clinically meaningful reductions in IOP from baseline (≤18 mmHg) with fewer ocular adverse events (13.9% vs. 22.5%). Less than 2% of patients in the Iyuzeh group experienced instillation site pain, pruritis or conjunctival hyperemia.”

“The harmful effects of preservatives on ocular surface health are well documented,” said Susan Benton, President of Thea Pharma. “We have solved the challenge of creating a room temperature-stable, efficacious, and preservative-free latanoprost eye drop. Iyuzeh brings the IOP-lowering efficacy of latanoprost and eliminates the exposure to preservatives for patients with glaucoma or ocular hypertension.”

Iyuzeh has been marketed outside of US under the brand name Monoprost in 46 countries. About 1.5 million patients are currently treated with Monoprost, which was launched 10 years ago. Iyuzeh will be launched in the US later this year.

AGS 2023 attendees and virtual registrants may view Dr. Bacharach’s presentation as part of the poster on-demand section of the meeting.